Клиническая конечная точка (Russian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Клиническая конечная точка" in Russian language version.

refsWebsite
Global rank Russian rank
2nd place
3rd place
1st place
1st place
4th place
6th place
1,684th place
5,668th place
2,467th place
4,656th place
6th place
9th place
447th place
541st place
low place
low place

archive.org

cancer.gov

doi.org

  • Penninckx, B (26 June 2012). "A systemic review of Toxic Death in clinical oncology trials: an Achilles' heel in safety reporting revisited". British Journal of Cancer. 107 (1): 1—6. doi:10.1038/bjc.2012.252. PMID 22677904.
  • Biomarkers Definitions Working Group (March 2001). "Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework". Clinical Pharmacology & Therapeutics. 69 (3): 89—95. doi:10.1067/mcp.2001.113989. PMID 11240971.
  • De Gruttola, Victor G (October 2001). "Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials". Controlled Clinical Trials. 22 (5): 485—502. doi:10.1016/S0197-2456(01)00153-2. PMID 11578783.
  • Cohn, J. N. (29 June 2004). "Introduction to Surrogate Markers". Circulation. 109 (25 suppl 1): IV–20–IV-21. doi:10.1161/01.CIR.0000133441.05780.1d. PMID 15226247.
  • Handforth, C. (October 2013). "Overall treatment utility: A novel outcome measure to convey the balance of benefits and harms from cancer treatment". Journal of Geriatric Oncology. 4: S49. doi:10.1016/j.jgo.2013.09.064.
  • Core Outcomes in Women's Health (CROWN) Initiative (2014). "The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health". Journal of Gynecologic Oncology. 25 (3): 166—7. doi:10.3802/jgo.2014.25.3.166. PMID 25045427.

fda.gov

mwsug.org

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Penninckx, B (26 June 2012). "A systemic review of Toxic Death in clinical oncology trials: an Achilles' heel in safety reporting revisited". British Journal of Cancer. 107 (1): 1—6. doi:10.1038/bjc.2012.252. PMID 22677904.
  • Biomarkers Definitions Working Group (March 2001). "Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework". Clinical Pharmacology & Therapeutics. 69 (3): 89—95. doi:10.1067/mcp.2001.113989. PMID 11240971.
  • De Gruttola, Victor G (October 2001). "Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials". Controlled Clinical Trials. 22 (5): 485—502. doi:10.1016/S0197-2456(01)00153-2. PMID 11578783.
  • Cohn, J. N. (29 June 2004). "Introduction to Surrogate Markers". Circulation. 109 (25 suppl 1): IV–20–IV-21. doi:10.1161/01.CIR.0000133441.05780.1d. PMID 15226247.
  • Core Outcomes in Women's Health (CROWN) Initiative (2014). "The CROWN Initiative: journal editors invite researchers to develop core outcomes in women's health". Journal of Gynecologic Oncology. 25 (3): 166—7. doi:10.3802/jgo.2014.25.3.166. PMID 25045427.

uu.nl

vet.uu.nl

web.archive.org